ArticleTheScientificWorldJournal2026
Neuropharmacological and Antipyretic Potentials of Streblus asper Leaves: Integrated In Vivo and In Silico Approaches.
Article in TheScientificWorldJournal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuropharmacological and Antipyretic Potentials of Streblus asper Leaves: Integrated In Vivo and In Silico Approaches.TheScientificWorldJournal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Streblus asper (Moraceae) is traditionally used for neurological and febrile disorders, but its pharmacological basis remains unclear. This study evaluated the S. asper leaf methanolic extract (SAL-ME) for anxiolytic, antidepressant, sedative, and antipyretic activities using Swiss albino mice and in silico docking analyses. Behavioral assays included the elevated plus maze, hole-board, forced swim, tail suspension, hole cross, and open field tests, while brewer's yeast-induced pyrexia was used to assess antipyretic activity. SAL-ME (200 and 400 mg/kg) produced dose-dependent effects, significantly reducing immobility time (p < 0.001), increasing open-arm exploration (p < 0.01), and suppressing locomotor activity, indicating antidepressant, anxiolytic, and sedative actions. A significant antipyretic effect was observed at 400 mg/kg, with a marked reduction in rectal temperature within 3 h posttreatment (p < 0.01). Molecular docking analysis revealed notable binding affinities of octadecanoic acid, hexadecanoic acid, D-pinitol, α-D-glucopyranoside, myo-inositol, and butanedioic acid with target proteins associated with GABAergic, serotonergic, and prostaglandin-mediated pathways. Collectively, these findings suggest that SAL-ME exerts dose-dependent, multitarget pharmacological effects, supporting its potential as a phytotherapeutic candidate for CNS disorders and fever.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.